B+
Bull case
28%
Probability
Target price
$2.40
+42.9% vs current
BIAF
bioAffinityANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
42%
Probability
Target price
$1.80
+7.1% vs current
B-
Bear case
30%
Probability
Target price
$0.80
-52.4% vs current
AI sentiment snapshot
Latest data as of 2026-05-29
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+48.1
Score
AI commentary
Recent issuer-led news flow is modestly constructive because Q1 unit sales and CyPath Lung revenue improved and the patent allowance adds incremental IP validation, but the setup is still dominated by financing risk, low coverage, and the absence of analyst target/revision evidence. Social context is unavailable, so confidence should stay cautious rather than extrapolative.
RankAlpha Sentiment Codex - 2026-05-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-08eventQ1 CyPath Lung growth supports the commercialization story but does not fix the loss profileHigh impact
The 10-Q shows CyPath Lung unit sales rose 146% year over year and CyPath Lung testing revenue increased about 114% to $361,000, but consolidated revenue fell about 36% to $1.35 million and the company still reported a $3.63 million net loss. The market is likely to keep focusing on whether unit momentum can convert into durable revenue and lower cash burn. [#10-Q-2026-05-11]
2026-05-27eventMexico patent allowance adds incremental IP validationHigh impact
On May 27, the company disclosed via 8-K that it received notification of allowance from the Mexican Institute of Industrial Property for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. This is supportive for platform defensibility, but it does not materially resolve financing or commercialization risk on its own. [#8-K-2026-05-27]
2026-06-30catalystLiquidity and dilution remain the primary near-term overhangHigh impact
The Q1 2026 10-Q says the company had about $3.1 million of cash and cash equivalents at March 31, 2026 and concludes there is substantial doubt about its ability to continue as a going concern for at least twelve months after issuance; the prior 10-K also indicated cash resources were expected to last only through June 2026 absent new financing. Any equity raise, warrant exercise, debt, or strategic capital event could move the stock sharply, but the balance of risk remains dilution-heavy. [#10-Q-2026-05-11] [#10-K-2026-03-16]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-29 • Updated nightlySource: Internal modelMethodology